Nicodicosapent

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameNicodicosapent
Drug Alias NameNiacin-eicosapentaenoic acid conjugateCAT-2003
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSterol regulatory element-binding protein 2 inhibitorsSterol regulatory element binding transcription factor 1 inhibitors
TargetsSterol regulatory element binding transcription factor 1Sterol regulatory element-binding protein 2
Therapy Area/IndicationsHypertriglyceridemiaHypercholesterolemiaHyperlipidemias +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCatabasis
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstria Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsHypertriglyceridemiaHypercholesterolemiaHyperlipidemias +[7] 

Other Information

ATC CodeN/A
Related LinksN/A